Sertraline
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
Sertraline: Histrionic personality disorder (disease)
One-Sentence Summary
Sertraline is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. The TxGNN model predicts it may be effective for histrionic personality disorder, but there are currently 0 clinical trials and 0 publications supporting this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Histrionic personality disorder (disease) |
| TxGNN Prediction Score | 0.9993 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on general knowledge, sertraline belongs to the SSRI class, which increases serotonin signalling in the brain. Its use in anxiety-related conditions is well established. Mechanistically, it may influence mood, anxiety and impulsivity, which are features that overlap with some personality disorders.
The model most likely assigns the high score because of closeness in the network of related personality and anxiety disorders, not because of disease-specific biology. Several neighbouring personality disorders (schizoid, paranoid, schizotypal) received an identical score of 0.9993, which supports this reading. No study in the compiled data tests sertraline in histrionic personality disorder, so the link remains a hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
At least 20 single-ingredient sertraline registrations were found, and the list may be partial. The five below are examples. The records do not include approved-indication text.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Registration No. 205564 | Setradox 50mg Tablet | Strip of 10 tablets | Not stated in the records |
| Registration No. 74165 | Elesert 25 Tablet | Strip of 10 tablets | Not stated in the records |
| Registration No. 58529 | Daxid 25mg Tablet (Pfizer Ltd) | Strip of 15 tablets | Not stated in the records |
| Registration No. 200878 | Serlin 50mg Tablet (Zydus Cadila) | Strip of 10 tablets | Not stated in the records |
| Registration No. 206513 | Sertane 100mg Tablet | Strip of 10 tablets | Not stated in the records |
Safety Considerations
- Contraindication-type relations in the knowledge graph (not label text): epilepsy, bipolar disorder, major affective disorder, liver disease, gallbladder disease, blood coagulation disease, neuroleptic malignant syndrome, inappropriate ADH syndrome, nephrogenic syndrome of inappropriate antidiuresis, serotonin syndrome.
- Drug Interactions: 396 interactions were recorded. Those rated Major among the first 20 listed include bupropion, lorcaserin, diethylpropion, dolasetron, eliglustat, palonosetron and phentermine. Moderate interactions include famotidine, loperamide, morphine, acetylsalicylic acid, clarithromycin and glimepiride.
Please refer to the package insert for label warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting clinical trials or publications for histrionic personality disorder. The high score appears to reflect network proximity to other personality and anxiety disorders. The evidence level is therefore L5.
However, it largely overlaps with anxiety indications already linked to sertraline, so it is not a distinct repurposing opportunity.
To proceed, the following is needed:
- Any clinical or observational study of sertraline specifically in histrionic personality disorder
- Mechanism of action data and a mechanistic rationale specific to this condition
- Package insert warnings and contraindications from the Indian regulatory records
- A drug interaction review for the likely co-medications in this population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.